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Abstract
Background: Polypharmacy (the concurrent use of more than one psychoactive drug) and other combination
interventions are increasingly common for treatment of severe psychiatric problems only partly responsive to
monotherapy. This practice and research on it raise scientific, clinical, and ethical issues such as additive side
effects, interactions, threshold for adding second drug, appropriate target measures, and (for studies) timing of
randomization. One challenging area for treatment is severe child aggression. Commonly-used medications, often
in combination, include psychostimulants, antipsychotics, mood stabilizers, and alpha-2 agonists, which vary
considerably in terms of perceived safety and efficacy.
Results: In designing our NIMH-funded trial of polypharmacy, we focused attention on the added benefit of a
second drug (risperidone) to the effect of the first (stimulant). We selected these two drugs because their
associated adverse events might neutralize each other (e.g., sleep delay and appetite decrease from stimulant
versus sedation and appetite increase from antipsychotic). Moreover, there was considerable evidence of efficacy
for each drug individually for the management of ADHD and child aggression. The study sample comprised
children (ages 6-12 years) with both diagnosed ADHD and disruptive behavior disorder (oppositional-defiant or
conduct disorder) accompanied by severe physical aggression. In a staged sequence, the medication with the least
problematic adverse effects (stimulant) was openly titrated in 3 weeks to optimal effect. Participants whose
behavioral symptoms were not normalized received additional double-blind medication, either risperidone or
placebo, by random assignment. Thus children whose behavioral symptoms were normalized with stimulant
medication were not exposed to an antipsychotic. All families participated in an empirically-supported parent
training program for disruptive behavior, so that the actual comparison was stimulant+parent training versus
stimulant+antipsychotic+parent training.
Conclusions: We hope that the resolutions of the challenges presented here will be useful to other investigators
and facilitate much-needed research on child psychiatric polypharmacy.
Trial Registration: ClinicalTrials.gov NCT00796302
Keywords: ADHD, disruptive behavior disorder, stimulant, risperidone, drug trial
Background
The Treatment of Severe Child Aggression (TOSCA)
study is a four-site NIMH-funded investigation of staged
polypharmacy with stimulant and antipsychotic medica-
tion with adjunctive behavioral treatment (parent train-
ing, PT). Development of the protocol encountered
numerous scientific, clinical, and ethical problems that
were resolved through iterative review cycles and 7
years of cross-site teleconferences. The solutions, which
may be useful to other investigators and clinicians, are
presented here in the interests of evaluating this and
other forms of polypharmacy.
Pharmacologic Treatment of ADHD, Disruptive
Behavior Disorders, and Aggression
Approximately one half of all referred children with
attention-deficit/hyperactivity disorder (ADHD) present
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conduct disorder (CD), known collectively as disruptive
behavior disorders (DBDs) [1]. Among the many psy-
chosocial interventions for these disorders, PT in beha-
vior management (also known as parent management
training) is one of the most effective [2-4]. The literature
suggests that such psychosocial interventions are the
first line of treatment for a DBD; however, maximal
effectiveness is often only achieved over time and may
even be ineffective in diminishing high levels of aggres-
sion [5]. Data from ADHD studies suggest that concur-
rent medication may boost the effectiveness of
behavioral treatment [6], and in the case of comorbid
ADHD and DBD, a combination of medication and
behavioral treatment is necessary for an optimal effect
[7]. A combination intervention may also result in the
use of lower overall doses of medication to achieve the
same response associated with monotherapy [8,9].
Psychopharmacologic Monotherapy
Much research has been devoted to pharmacotherapy
for aggressive behavior in prepubertal children in part
because it is associated with significant immediate
impact in academic and social functioning [10] and con-
siderable psychosocial burden. More troubling is the
lack of spontaneous remission and consequent later
delinquency, substance abuse, sexual promiscuity, and
other psychopathology [11]. Research has focused pre-
dominantly on four classes of medication: psychostimu-
lants, antipsychotics, mood stabilizers, and a-2 agonists.
Psychostimulants
Psychostimulants, including methylphenidate and
amphetamine preparations, are the most commonly-pre-
scribed medications for treating ADHD and boast a
large volume of literature supporting their efficacy [12].
Longer-term safety and efficacy has also been demon-
strated in multiple investigations [13,14]. Although sti-
mulants have been shown to ameliorate aggressive
behavior in children with ADHD, comorbidity with CD
is associated with lessened efficacy [15]. For example, a
large, rigorous study of psychostimulants in children
with both ADHD and CD found that active medication
was superior to placebo in reducing symptoms of both
disorders, though symptoms of CD at endpoint were
not generally normalized [16].
Mood Stabilizers
Lithium was the first mood stabilizer shown to be effec-
tive in reducing aggressive behavior in children with CD
in the 1980s [17-19], though at least one trial found no
difference from placebo over two weeks [20]. Methodo-
logically rigorous studies of divalproex found it to be
superior to placebo in treating explosive temper and
mood lability [21] and CD [22] in adolescents. Both
divalproex and lithium require vigilant blood
monitoring, which is unappealing to many patients and
professionals. Mixed evidence has been found for carba-
mazepine, which was shown to be effective in a pilot
study [23], but a later double-blind, placebo-controlled
study failed to demonstrate effectiveness [24]. Overall,
certain mood stabilizers may deserve further study, but
their potential for serious adverse events (AEs) makes
other drug classes more attractive.
Alpha-2 Agonists
Alpha-2 agonists (e.g., clonidine and guanfacine) alone
are effective in treating ADHD symptoms [25,26],
although usually less so than psychostimulants. A pilot
study produced preliminary support for clonidine alone
or in combination with stimulant for treating ADHD
and DBD [27]. In a double-blind, placebo-controlled
study, Hazell and Stuart [28] showed a significant effect
of clonidine on parent-rated conduct symptoms (but not
on teacher ratings of CD). Both guanfacine extended
release (XR) and clonidine XR have FDA approval for
ADHD [29,30]. The a-2 agonists deserve further study
in co-morbid ADHD plus DBD.
Atypical Antipsychotics
Atypical antipsychotics are putatively more attractive
than conventional antipsychotics due to reduced risk of
extrapyramidal side effects. Olanzapine, quetiapine, and
aripiprazole all have some evidence to support their effi-
cacy in treating aggressive behavior, but many of the
studies are open-label or retrospective chart reviews
[31]. Weight gain is the most commonly observed AE
with these medications.
In children, risperidone is the most frequently studied
of the atypical antipsychotics. The first study of risperi-
done in children with CD found it to be superior to pla-
cebo in reducing parent- and clinician-rated measures of
aggressive behavior [32]. Several large, randomized con-
trolled trials have been completed in the intervening
decade. Two studies showed risperidone to be superior
to placebo in ameliorating hostile and aggressive beha-
vior in children with DBD and subaverage IQ [33,34].
Open-label 48 week follow-ups of both studies found
risperidone to be well-tolerated and effective [35,36].
Significant AEs include weight gain and elevated prolac-
tin levels. However, pooled data suggested that risperi-
done does not negatively impact either growth or sexual
maturation in children and adolescents over the long
term [37]. Although risperidone has the most positive
evidence of the atypical antipsychotics and is the most
studied, the possible weight gain (with risk of conse-
quent metabolic syndrome) and increased prolactin
levels warrant continued monitoring. It is also worth
noting that much of the research on atypical antipsycho-
tics has been carried out in samples with below-average
IQ; there are few high-quality data in samples with aver-
age IQ.
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Despite the well-documented efficacy of stimulant mono-
therapy, a considerable number of youth with both
ADHD and aggression continue to manifest symptoms
and impairment [38,39]. A meta-analysis of 28 studies
demonstrated that effect sizes vary widely in treatment
for aggression in children with ADHD, which leaves a
clinical quandary of what to do with non-responders [15].
Polypharmacy is common in most areas of medicine
(e.g., cardiology, cancer, or seizure treatment), and is
becoming more widespread and respectable in psychia-
try despite a previous pejorative connotation. One possi-
ble reason for the lag in polypharmacy psychiatric
research is a relative lack of interest by drug companies
in mental health. In a United States-based survey from
the early 2000s, over 40% of child and adolescent psy-
chiatric patients were prescribed two or more medica-
tions [40]. Patients with chronic and clinically complex
conditions were more likely to receive concomitant
pharmacotherapy. In an analysis of annual data from the
1996-2007 United States National Ambulatory Medical
Care Surveys, there was an increase in the percentage of
pediatric patients who were prescribed medication from
at least two psychotropic drug classes [41]. During the
12-year period, multiclass psychotropic treatment rose
from 14% of visits to 20%.
Combined pharmacotherapy is often used in patients
who demonstrate only partial response to monotherapy,
but is also useful in a variety of other contexts, includ-
ing the treatment of comorbid disorders and as adjunc-
tive therapy associated with adverse events. Combining
medications with different mechanisms of action makes
conceptual sense in refractory cases, and combinations
of drugs with reciprocally neutralizing adverse events
(AEs; e.g., blood pressure, pulse, weight, and sedation)
are particularly appealing. Nevertheless, despite wide-
spread polypharmacy, there are few published data
about controlled polypharmacy or co-administration
trials in ADHD [42] and/or DBDs; the available litera-
ture is reviewed below.
The different mechanisms of action of psychostimu-
lants and a2-adrenoceptor agonists may lead to additive
beneficial effects treating ADHD and/or associated pro-
blems [26] and has become common clinical practice.
The joint use of an a-2 agonist and a psychostimulant
for ADHD and DBD has been tentatively endorsed by
some treatment guidelines [42,43]. Both guanfacine XR
and extended-release clonidine are FDA-approved as
both adjunctive therapy and monotherapy for treating
ADHD. Several trials have shown alpha-agonist and psy-
chostimulant to be more effective than monotherapy in
reducing ADHD symptoms [44-46].
Mood stabilizers have also been considered as
adjuncts to psychostimulant treatment. Following an
open lead-in of psychostimulant, Blader et al. [47] ran-
domized children and adolescents with ADHD and
aggression to an 8-week, double-blind, placebo-con-
trolled trial of divalproex. Remission was observed in
nearly 60% of children randomized to divalproex, com-
pared to 15% of the placebo group. Divalproex was asso-
ciated with higher rates of sadness and insomnia than
placebo.
Considerable attention has been given to adjunctive
atypical antipsychotic use in children and adolescents
[41]. For example, Kronenberger and associates [48]
added quetiapine to methylphenidate treatment-resistant
adolescents with ADHD, DBD, and aggression. The
combination was more effective in control of both
ADHD and aggressive symptoms than the methylpheni-
date alone. Two studies focused largely on the tolerabil-
ity/safety of using stimulants and atypical antipsychotics.
In a naturalistic study, Penzner et al. [49] examined chil-
dren and adolescents receiving various atypical antipsy-
chotics and concurrent stimulants. At 12 weeks,
stimulant co-administration did not alter the effects of
the antipsychotic on body composition or metabolic
indices. However, a similar study found disparate results
[50]. Despite the use of low antipsychotic doses, conco-
mitant stimulants, and initially low body mass index z-
scores, a significant proportion of children treated with
combined atypical antipsychotic and stimulant devel-
oped one or more criteria for metabolic syndrome.
Thus, metabolic and weight gain issues remain of criti-
cal importance despite coadministration of
psychostimulant.
Although these studies help to frame key issues
regarding the use of polypharmacy in treating ADHD
with DBD, they also have limitations involving (a)
blinded status, (b) randomization, (c) placebo control,
(d) sequential titration of medications, and/or (e)
longer-term follow-up to ascertain ongoing efficacy and
safety of chronic use.
It is a curious fact members of the scientific commu-
nity have engaged in few broadly-based and vigorous
examinations of the merits and liabilities associated with
polypharmacy for treating young people with psychiatric
problems. Although there are some preliminary data,
existing studies are limited in advancing such a discus-
sion. We hope that the following study will help to
inform the discussion about the use of a common form
of polypharmacy for managing aggression and hostility
associated with co-morbid ADHD and DBD.
Design Challenges
Final Study Design
Figure 1 shows the final design of the parallel-groups
randomized clinical trial. The participants were 160 chil-
dren aged 6 to 12 years (inclusive), with ADHD, ODD
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aggressive behavior was defined as a score of three or
greater on the Modified Overt Aggression Scale and a
score greater than 26 (> 90
th percentile) on the Nisonger
Child Behavior Checklist Disruptive Total (NCBRF D-
Total) subscale. The children were randomized in a 1:1
ratio to two 9-week treatment strategies: stimulant alone
for three weeks and, if residual symptoms remained, ris-
peridone or placebo added for six weeks. Dosing for
both medications was optimized by weight (see titration
schedules in Table 1). Osmotic Release Oral System
(OROS) methylphenidate (Concerta) was initiated at 18
mg each morning and titrated up to a limit of 54 mg or
72 mg (depending on weight) by Week 2. Risperidone
was initiated at 0.5 mg each evening and titrated up to a
total daily limit of 2.5 mg or 3.5 mg, depending on
weight. Dosage was held at a lower level or reduced if
limiting side effects developed or if clinical improvement
left no meaningful room for further improvement. To be
consistent with recommended practice and to keep the
study ecologically valid, the parents/guardians of all par-
ticipants received parent training (PT) in strategies of
behavior management. The double-blind was maintained
in a three-month extension for those deemed respon-
ders (CGI-I of 1 or 2, plus greater than 25% reduction
in NCBRF D-Total) at Week 9. This extension provided
the opportunity to observe whether the short-term
effects were maintained over the medium-term. Finally,
a one-year follow-up (Week 52) was sought for all parti-
cipants, in order to assess feasibility, efficacy, and safety
over the long term.
Trial Design Challenges
One challenging design issue was the selection of possi-
ble treatment arms. Beyond a simple placebo arm, there
were several options under consideration, including: (a)
random assignment to three conditions (each drug
alone and their combination); (b) random assignment to
two conditions, one drug alone or to both drugs; (c)
random assignment to drug A with drug B to be added
or the reverse; and (d) open-label administration of one
drug with a randomly-assigned second drug (or placebo)
to be added if needed at a predefined time with a prede-
fined threshold. The first three options required expo-
sure to both drugs by random assignment rather than
demonstrated need. This was an ethical concern recog-
nized by both the TOSCA investigators and the NIH
review committee, and we therefore adopted the fourth
option. We decided first to try the stimulant owing to
its more favorable AE record and then to add the anti-
psychotic if needed. In order to remain in the stimulant-
Figure 1 At screen, arrangements were made to discontinue
most medicines for 2 weeks. Fluoxetine and antipsychotics were
washed out for 4 weeks. At baseline, participants were randomized
to psychostimulant (STIM; usually OROS methylphenidate) plus
placebo or combined (STIM + risperidone [RIS]) treatment.
1If
subjects did not demonstrate sufficient improvement by end of
Week 3 (defined as normative value + 0.5 standard deviation on the
NCBRF D-Total score), PBO/RIS was added to treatment. At end of
Week 9, subjects were classified as clinical responders (CGI-I = 1 or
2 and NCBRF Disruptive Total reduced by 25% relative to baseline).
2Responders were followed on their originally assigned conditions
for 12 weeks of double-blinded Extension. Nonresponders were
treated clinically as appropriate, based on the study team’s best
judgment. On the one-year anniversary date from baseline, all
participants were asked to return for a follow-up assessment.
Table 1 Dosing and Titration Guidelines
OROS
Methylphenidate
Risperidone
Day < 25 kg > 25 kg Day 20-45 kg > 45 kg
AM PM AM PM
1-4 18 mg 18 mg 1 - 0.5 mg - 0.5 mg
5-7 18 mg 36 mg 4 0.5 mg 0.5 mg 0.5 mg 0.5 mg
8-11 36 mg 54 mg 8 0.5 mg 1.0 mg 0.5 mg 1.0 mg
12-14 54 mg 72 mg 11 - - 1.0 mg 1.0 mg
15+ Maintenance;
Dose reduction
allowed for side effects
15 - - 1.0 mg 1.5 mg
16 1.0 mg 1.0 mg - -
18 - - 1.5 mg 1.5 mg
22 1.0 mg 1.5 mg 1.5 mg 2.0 mg
29 1.0 mg 1.5 mg 1.5 mg 2.0 mg
The study prescriber could vary from the guidelines as clinically indicated. In
particular, the dose could be held constant or reduced for limiting side effects
or if the clinical status left no room for further improvement.
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one-half standard deviation of the mean for a normative
sample on the main outcome measure of ODD beha-
viors (including aggression; NCBRF D-Total) and aC G I
Improvement rating of “Very much improved.”
Timing of Randomization
A related issue pertained to the timing of randomiza-
tion, which was partially determined by the review pro-
cess. Once we decided the stimulant medication should
be openly titrated and the second medicine (risperidone)
added if needed, we proposed to randomize less-than-
optimal stimulant responders to either risperidone or
placebo for six weeks. This strategy seemed cleanest,
with the intent-to-treat (ITT)a n a l y s e sc o n f i n e dt os t i -
mulant poor responders, but the NIMH review commit-
tee was concerned about attrition before the
randomization. Therefore, we decided to randomize
enrolled subjects at baseline to the two treatment strate-
gies: stimulant plus placebo versus stimulant plus risper-
idone. However, only those participants who evidenced
less-than-optimal response to stimulant were actually
given the second medication (placebo or risperidone).
Details on the timing of second medication are dis-
cussed in a later section. In retrospect this strategy
appears to have been unnecessary, as we had relatively
little attrition prior to randomization. However, our
adopted strategy had two related advantages: it is com-
patible with (though not identical to) the choices that a
prescriber faces, and it directly answers the question of
whether anticipating combined drug therapy from the
beginning is a good treatment strategy.
Placebo or not?
An additional consideration we faced was the inclusion
of a placebo arm. Ideally, it would be optimal to com-
pare groups of children treated with each drug sepa-
rately and their combination to a fourth group who
received placebo only. A two-by-two design could
accomplish this, using a double-placebo with all partici-
pants taking two kinds of pills, each of which could be
either placebo or active. However this design would pre-
scribe polypharmacy as a result of randomization rather
than clinical need, leaving us with ethical reservations
about exposing some patients to the added risk of the
second drug unnecessarily. Conversely, because numer-
ous well-controlled studies had established the efficacy
of both drugs versus placebo, it could have been argued
that a placebo-alone arm may have unnecessarily
increased the cost of the study as well as delayed treat-
ment for patients deemed sick enough to benefit from
the combination of two drugs. Ultimately, the practical
realities of conducting such a study determined the
course of action. The funds that NIMH could afford to
invest in TOSCA would not accommodate a placebo
arm. In retrospect, this was fortunate, as many of the
highly stressed and often fragile families who qualified
for TOSCA have encountered difficulty adhering to
treatment known to be active and would likely have
found it impossible to weather a placebo assignment.
Another benefit was incurred during recruitment
b e c a u s ew ew e r ea b l et oi n f o r mp o t e n t i a lp a r t i c i p a n t s
that everyone would get two treatments (PT and stimu-
lant) and half would be randomized to get a third treat-
ment if needed.
Selection of Psychosocial Treatment
The selection of concurrent PT was driven by two
important factors. The most pressing was the desire to
provide active therapy to participants randomized to the
stimulant plus placebo arm. Also important, however,
was the notion that federally-funded research is charged
with examining treatments using best clinical practices.
O w i n gt op o w e r f u lc u l t u r a lb eliefs that DBDs are more
environmentally driven than CNS diseases such as schi-
zophrenia [51], we concluded that youth with aggression
should be treated first with behavioral intervention prior
to the administration of antipsychotic medication. Ulti-
mately, this propelled us into a design that offered the
best currently available interventions (PT and psychotro-
pic medication).
We opted to use a conventional behavioral parent
training approach that emphasized the basics of positive
reinforcement, planned ignoring, promoting positive
transitions, incentive systems, collaborative parent-child
planning, and time-out [52]. The approach used, an
adaptation of Community Parent Education (COPE),
provided for individual application to each family and
child regardless of age, clinician modeling of the inter-
vention, and parent-clinician role play practice of the
intervention as applied to each child.
Medication Selection
Medication selection was based in large part on the fol-
lowing: prior research demonstrating the efficacy of
each drug’s monotherapy, actual prescribing patterns in
the United Sates (including polypharmacy), evidence for
acceptability, and the possibility of beneficial interactive
effects, both therapeutic and untoward, owing to diverse
mechanisms of actions. Our initial choice was divalproex
because of its common clinical use in the target popula-
tion. However, in two consecutive submissions, indivi-
dual reviewers were adamantly opposed to the choice of
divalproex, citing adverse events and limited data sup-
porting efficacy.
It was fortuitous that two of the most commonly pre-
scribed drugs for child aggression may have potentially
offsetting AEs. Stimulants may depress appetite, inter-
fere with sleep, and induce rebound irritability (as they
wear off at the end of the day). Conversely, antipsycho-
tics may increase appetite, cause sedation, and have
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effects when treatment is abruptly terminated. This
seemed to offer reasonable hope that the combination
may be associated with fewer side effects than either
alone; one aim of the study was to assess AEs as well as
additive benefit. Additionally, the soaring popularity of
atypical agents and attendant concerns of advocacy
groups calling for more controlled trials in children
made risperidone an obvious choice. Thus, we settled
upon treatment with psychostimulant followed, if neces-
sary, by risperidone versus placebo.
Although the stimulant of first choice in this trial was
OROS methylphenidate owing primarily to its extended
duration of action, it was not mandated in the protocol
so as not to exclude children who had prior poor
response or who had difficulty swallowing pills. It was
required that the substituted medication be a stimulant
because the addition of non-stimulant ADHD medica-
tions would have introduced “noise” into the analyses. In
such cases, the dosage was matched in potency to the
OROS methylphenidate taken by most other participants.
This was consistent with common clinical practice in the
United States, where a tolerable stimulant would ordina-
rily be sought before adding an antipsychotic.
Timing of Second Medication
It was necessary to decide how long to allow for an
effect of stimulant before adding the second medication.
The literature suggests the treatment effects of a given
dose are observed within a day after initial administra-
tion [53]. Therefore, we decided that stimulant mono-
therapy could be titrated within two weeks by making
use of mid-week adjustments and allowing a third week
to observe the effect of the optimal dose. At the end of
Week 3 stimulant response was assessed and a decision
made about adding the second medication. However, if
the second drug was not needed at Week 3 and the
child’s behavior subsequently deteriorated on the opti-
mal stimulant dose, the prescriber was able to add the
second medication through the sixth week of the study.
This would allow at least three weeks for detection of
any effect that the second medication might have. This
rescue policy was important because an ITT analysis
was proposed to analyze the data from each child within
the group to which (s)he was randomized, regardless of
whether or not the second medication was actually
taken. Therefore, constraining the addition of the sec-
ond medication exclusively to the Week 3 visit would
have had deleterious effects on our ability to show an
additive effect, as well asd o i n gt h ec h i l dac l i n i c a l
disservice.
Instrumentation
An important component of any study is the selection
of appropriate measures. In the current study, it was
necessary to assess multiple behavioral constructs. Addi-
tionally, the instruments used to assess AEs were
required to span several categories relevant to both sti-
mulant and antipsychotic medications. Here we present
the rationale for the selection of our main study
instruments.
Primary and Secondary Outcomes
Table 2 contains an abbreviated schedule of measures
constrained to those relevant to polypharmacy issues.
The main behavioral constructs of interest were symp-
toms of ADHD, ODD/CD, and aggression. To that end,
the primary outcome measure was the parent-completed
N C B R FD i s r u p t i v e - T o t a ls c o r e .T h eN C B R F[ 5 4 ]f o r
typically-developing children has one Prosocial subscale
and six Problem Behavior subscales (Conduct Problem,
Oppositional Behavior, Hyperactive, Inattentive, Overly
Sensitive, and Withdrawn/Dysphoric). The D-Total is
the sum of the Conduct Problem and Oppositional
Behavior subscales. We felt that it represented the range
of behaviors expected to improve with the combined
treatment (i.e., pharmacological and behavioral). It has
excellent psychometric characteristics and, based on
findings with the developmental delay version in sam-
ples of children with cognitive delay [33], we expected it
to be highly treatment-sensitive.
Secondary measures included the Clinical Global
Impressions Scale (CGI) [55] Severity and Improvement,
and the Standard Observation Analogue Procedure
(SOAP) [56]. The Standard Observation Analogue Pro-
cedure (SOAP) is a direct observation procedure that
provides an objective video record of caregiver-child
interactions for purposes of assessing caregiver skill
acquisition and child response to intervention. The
SOAP was included to provide an objective index
(coders are blinded to treatment assignment) that can
be used to verify parent/teacher/clinician ratings of
behavior. We also anticipated that the SOAP might be
helpful in assessing change in parental behavior as a
result of PT.
T h e r ei ss o m ee v i d e n c et os u g g e s tt h a tc e r t a i ns u b -
types of aggressive behavior might be more responsive
to pharmacologic treatment [57]. Thus, proactive and
reactive aggression are assessed with the Antisocial
Behavior Scale (ABS) [58], which contains a Proactive
Aggression subscale (five proactive items and five covert
antisocial items) and a Reactive Aggression subscale (six
items). For a similar reason (i.e., potential moderation),
the short version (27 items) of the MacMaster Family
Assessment Device [59] was used to characterize the
family system, which is often chaotic in this study popu-
lation and might influence response to treatment.
Other Measures
The Modified Overt Aggression Scale (M-OAS) [60] has
seven items: verbal assault; assaults against objects,
Farmer et al. Child and Adolescent Psychiatry and Mental Health 2011, 5:36
http://www.capmh.com/content/5/1/36
Page 6 of 11against others, against self; global subjective irritability;
global overt irritability, and suicidal tendencies. This
study made use of three items: (a) assault against
objects, (b) assault against others, and (c) assault against
self. Each of the items is rated on a scale from zero (no
events) to five, where a higher number indicates greater
severity. We created an additional selection ("3b”)
wherein the rating is chosen if the child would have
completed the behavior, but was prevented by the par-
ent or caregiver; this rating was especially useful for
younger children, whose behavior is perhaps more easily
contained by parental intervention. The M-OAS has
been used in a number of descriptive and pharmacologi-
cal trials, but it has been used more in adults than for
young persons. Thus, it was used in this study only as
an entry threshold criterion (a score of three or greater
on one or more of the items). This degree of aggression
was considered ethically necessary to justify the risk of
antipsychotic drug.
The population from which this study drew is diag-
nostically complex. The behaviors observed in children
with ADHD and DBD are often similar to those found
in mood disorders. Psychosis, mood disorder, and major
depression were exclusionary in this study. We screened
for these disorders in two ways: The Kiddie Schedule
for Affective Disorders and Schizophrenia [61,62], a
semi-structured diagnostic instrument administered to
both parent/guardian and child by a trained interviewer
with clinical experience, was the primary source of diag-
nostic information. A second screen for the presence of
mood disorder was the parent-rated using the General
Behavior Inventory [63].
The Child and Adolescent Symptom Inventory-4R
(CASI-4R) [64] is a 147-item parent- and teacher-com-
pleted rating scale for evaluating youth 5 to 18 years.
Individual items bear one-to-one correspondence with
DSM-IV symptoms. Therefore, parent and teacher
reports on the ADHD and Peer Conflict scales (known
together as the ADHD Symptom Checklist-4) [65] were
assessed at every study visit. In addition, the full CASI-
4R was collected at key points in the study (screen,
baseline, and endpoints). The CASI-4R subscales were a
source of potential moderators of treatment response
and helped us to detect pharmacological effects on a
wide array of outcomes that might not otherwise be
covered.
Teacher Ratings
Although obtaining information from school personnel
about therapeutic response and untoward reactions is
for many an essential element in a best practices design,
this can also create many challenges for longer-term
designs. Limiting the completion of the full study to
coincide with the school year would greatly restrict
recruitment and increase cost burden. Our solution to
Table 2 Abbreviated Schedule of Measures
Measure or Procedure Screen W0 W1-2 W3 W4-8 W9 W13-17 W21 W52
Diagnostic Assessments (Screen only)
Kiddie Schedule for Affective Disorders X
General Behavior Inventory X
Medical Clinician
Blood draw XX X X
Vitals, Height, Weight, AEs X XXXXX X XX
Concomitant Medications X XXXXX X XX
Blinded Clinician
Family Assessment Device X
Modified Overt Aggression Scale (Inclusion) X
Antisocial Behavior Scale XX X
Standardized Observation Analogue Procedure XX X
Child Symptom Inventory-4R XX X
Symptom Checklist-4 X XXXXX X XX
Nisonger Child Behavior Rating Form XX X X XX X X
Clinical Global Impressions-Improvement XXXXX X XX
Clinical Global Impressions-Severity XX X X X X
Teacher Ratings
Antisocial Behavior Scale XX X
Child Symptom Inventory-4R XX X
Symptom Checklist-4 XXXXX X XX
Stimulant Side Effects XXXXX X XX
Cells marked with an X indicate visits in which the assessment was performed.
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tion (see Table 2) from the current teacher. During the
clinical trial, ratings were obtained from teachers for all
assessment periods for which school was in session,
making accommodations for school holidays when
necessary. This method of combining ratings from dif-
ferent sources is likely suboptimal; however, in some
cases, this was the only viable alternative.
Adverse Events/Safety Assessment
Safety is a particularly important and understudied issue
in polypharmacy. Due to the use of two separate drug
classes, it was necessary to assess several areas of poten-
tial adverse events. A specific emphasis was placed on
extrapyramidal symptoms, appetite, weight, sleep pat-
terns, and metabolic aberrations, as these AEs are com-
monly associated with the study drugs. Two parent
report AE scales were used; one specific to stimulants,
the other specific to antipsychotics. Both were based on
A E sl i s t e di np a c k a g ei n s e r t sa n dw e r eu s e di np r e v i o u s
studies. Treatment-induced motor disturbances were
assessed with three clinician-completed measures. The
Abnormal Involuntary Movement Scale (AIMS) [55] is a
standardized clinician-rated review of tremor, dyskinesia,
and other “active” neuromotor side effects. The Simp-
son-Angus Rating Scale [66] complements the AIMS in
checking for “passive” extrapyramidal side effects (rigid-
ity, dystonia, and abnormal glabellar reflex). The Barnes
A k a t h i s i aS c a l e[ 6 7 ]i saf o u r - i t e ms c a l ew i t ht w oi t e m s
based on observation by the rater and two items reflect-
ing the patient’s experience of restlessness.
Clinical laboratory tests checked for metabolic effects
of the antipsychotic, including complete blood count,
liver enzymes, lipids, fasting glucose, hemoglobin A1c,
and prolactin. All participants were administered an
electrocardiogram at screen and endpoint. Vital signs
included heart rate and blood pressure, possibly affected
by both drugs. Given the prominence of weight change
with both medications, height, weight, and hip-waist
ratio were also collected.
Statistical Considerations
In a two-drug additive design the primary analysis
should measure the effect of the second drug when
added to the first. This could be done in two ways. One
would be to take a new baseline before the second drug
is added and analyze the change score from the new
baseline to endpoint between those receiving placebo
and those receiving the second drug. Although this has
the advantage of clearly focusing on additive effect, it is
most appropriate if randomization occurs at the point of
adding the second drug. Because we randomized before
starting the first drug, we were comparing the mono-
therapy strategy to the strategy of adding a second drug
if needed. Therefore we primarily compared the change
scores in NCBRF D-total from Baseline to Week 9
between the two treatment strategies. Data from all ran-
domized subjects were included based on ITT princi-
ples. Linear mixed effects models were used to analyze
the repeatedly measured outcomes.
A preliminary statistical challenge was the power ana-
lysis, which had to be based on the expected additive
effect. The additive effect can be quite different from
the placebo-controlled effect size (ES) of either single
drug. Further, the ES can be diminished by the conco-
mitant parent training provided for ethical and recruit-
ment reasons in this study.A m a n ,B i n d e r ,a n dT u r g a y
[68] showed an ES of Cohen’s d =0 . 8 1w h e nr i s p e r i -
done was added to pre-existing stimulant without PMT,
but the stimulant was neither given prospectively nor
was the dose optimized in that study. Taking into
account the effect of PMT, we conservatively estimated
an ES of Cohen’s d = 0.5 for the difference between
treatment with one and two drugs, where there would
be a difference of 5.5 and a common standard deviation
of 11 in the NCBRF D-Total change scores between the
two treatment groups. With complete data on 124 sub-
jects (64 per group), we would be able to detect such an
ES with 80% power using a two-sample t- t e s ta tat w o -
sided type I error rate of 0.05. To allow for a possible
20% dropout rate prior to the second drug, we recruited
about 80 subjects per group. Randomization at baseline
was blocked on site and diagnosis (ODD vs. CD) to
allow for post-hoc tests of differential treatment effects.
Linear mixed effects models can handle missing data
based on the untestable assumption that unobserved
values are missing at random, though efforts were made
to minimize missing data during the trial. Last-observa-
tion-carried-forward was used to check the sensitivity of
the primary analysis to the assumption that data were
missing at random.
Study Monitoring
The study design developed for TOSCA also posed
unique challenges for cross-site study monitoring. As in
any medication trial, it was important to insure that the
titration protocol was followed uniformly across sites for
both medications. In this regard, it was particularly chal-
lenging to ensure that the first medication was ade-
quately titrated before the second medication was
added, because the protocol prohibited dose increases of
stimulant following the addition of risperidone/placebo.
The multiple decision points in this study dictated dif-
ferent definitions of “responder.” At the Week 3 visit,
children with a CGI-I of 1 and a NCBRF D-Total score
below 15 (e.g., within 0.5 SD of the normative mean)
were considered superb responders to stimulant, not
requiring the second medication; by protocol, others
were to receive the second drug. Our rationale was that
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tion if there was room for improvement. A different
definition of “responder” w a su s e da tt h eW e e k9d e c i -
sion point. Children with a CGI-I of 1 or 2 and a
NCBRF D-Total score that was improved at least 25%
relative to baseline were considered responders at Week
9 and were enrolled in the three-month Extension;
others exited the study to personalized clinical care.
These different definitions of clinical responder added a
degree of complexity not usually found in drug studies.
Thus cross-site fidelity monitoring was needed to verify
that the two different definitions of responder were
applied at their appropriate decision points.
Clinical Significance
The use of polypharmacy to treat disruptive behavior
disorders and ADHD has become standard practice in
the United States without adequate pertinent data. The
existing literature provides some support, but also sug-
gests concerns. Rigorous studies of polypharmacy are
complicated by scientific, ethical, and practical issues.
Scientific challenges include the choice of drugs, dosing
and timing of the combination, assessment of drug
effects, and the advisability of a placebo. Ethical con-
cerns regarding the possible unnecessary addition of a
second drug or the lack of a necessary addition (i.e., pla-
cebo) in severe cases are important considerations in the
trial design. Finally, practical challenges such as the
additional expense of a second medication, the concern
of regulatory bodies such as institutional review boards
or data safety monitoring boards regarding polyphar-
macy, and the administration of several treatments con-
comitantly are unique to polypharmacy studies. We
hope that the resolutions of these challenges presented
here will be useful to other investigators and facilitate
much-needed research on polypharmacy.
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